Evaluating the impact of human papillomavirus vaccines

Abstract While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effective...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-07, Vol.27 (32), p.4355-4362
Main Authors: Chang, Yuli, Brewer, Noel T, Rinas, Allen C, Schmitt, Karla, Smith, Jennifer S
Format: Article
Language:English
Subjects:
Allergy and Immunology
Applied microbiology
Biological and medical sciences
Cervical abnormalities
Cervical cancer
Female
Fundamental and applied biological sciences. Psychology
HPV vaccine effectiveness
Human papillomavirus
Humans
Immunization
Medical sciences
Microbiology
Miscellaneous
Papillomaviridae - classification
Papillomaviridae - immunology
Papillomaviridae - isolation & purification
Papillomavirus Infections - epidemiology
Papillomavirus Infections - immunology
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - immunology
Tumors
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - immunology
Uterine Cervical Neoplasms - prevention & control
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal). While research on the vaccines’ effects on these HPV clinical outcomes in the general population is presently limited, numerous large trials will soon be completed, making a priori discussion of these potential outcomes especially urgent. Furthermore, population level systems to track HPV-associated clinical outcomes may need to be developed for HPV vaccine effectiveness evaluation.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.03.008